NUVALOP-ER 250 TABLETS

Product Details :

Feature	Details
Product Name	NUVALOP-ER 250 Tablets
Form	Extended-Release Tablets
Key Ingredients	Sodium Valproate + Valproic Acid (combined strength: 250 mg)
Core Benefits	Seizure control, mood stabilization, migraine prevention
Support Areas	Epilepsy, bipolar disorder, migraine prophylaxis
Recommended Usage	As prescribed by a neurologist or healthcare professional
Target Audience	Adults and children requiring controlled valproate therapy

Composition: Divalproex Sodium Extended Release 250mg Packing: 10X10 Alu-Alu Description : NUVALOP-ER 250 Tablets contain a combination of Sodium Valproate and Valproic Acid (total 250 mg) in an extended-release formulation, designed for the management of epilepsy, bipolar disorder, and migraine prevention. The ER (Extended Release) technology provides a stable drug release over time, reducing the frequency and severity of seizures and mood swings. NUVALOP-ER 250 is ideal for pediatric and adult patients requiring a lower initial dose or dose adjustment during therapy. It is effective, well-tolerated, and used under medical supervision.